Updates are available Correction dated 2025-03-06

Article History

Received: 24 May 2024

Accepted: 25 June 2024

First Online: 30 July 2024

Change Date: 3 March 2025

Change Type: Update

Change Details: Formatting errors updated

Change Date: 6 March 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13555-024-01317-7

Declarations

:

: April W. Armstrong has served as a research investigator, scientific advisor, and/or speaker for AbbVie, Almirall, Arcutis, Aslan Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI Health, Incyte, Janssen, Leo Pharma, Lilly, Mindera Health, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Matthias Augustin has served on advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Janssen Biotech, and Leo Pharma; has received consulting fees from AbbVie, Amgen, Janssen Biotech, Leo Pharma, Lilly, Novartis, Sun Pharma, and UCB; has received honoraria from AbbVie, Amgen, Boehringer Ingelheim, Janssen Biotech, Leo Pharma, Lilly, Novartis, Sun Pharma, and UCB; served as an investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Janssen Biotech, Leo Pharma, Lilly, Merck, Novartis, Sun Pharma, and UCB; received research grants from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Janssen Biotech, Leo Pharma, Merck, and Sun Pharma; and served as a speaker for AbbVie, Amgen, Janssen Biotech, Leo Pharma, Sun Pharma, and UCB. Jennifer L. Beaumont, Tan P. Pham, and Stacie Hudgens served as consultants and received funding to conduct the analytic planning and execution activities associated with this research. Kenneth B. Gordon has received grant support and consulting fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, and UCB, and consulting fees from Amgen, Almirall, Dermira, Leo Pharma, Pfizer, and Sun Pharma. Joe Zhuo, Brandon Becker, Yichen Zhong, Renata Kisa, and Subhashis Banerjee are employees of and may own shares in Bristol Myers Squibb. Kim A. Papp has served as a consultant for AbbVie, Acelyrin, Akros, Amgen, Aralez Pharmaceuticals, Arcutis, Avillion, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite BioPharma, Celgene, Celltrion, Coherus, Dermavant, Dermira, Dice Therapeutics, Dow Pharma, Evelo, Forbion, Galderma, Incyte, Janssen, Kyowa Hakko Kirin, Leo Pharma, Lilly, Meiji Seika Pharma, Merck, Mitsubishi Pharma, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi Genzyme, Sandoz, Sun Pharma, Takeda, UCB, vTv Therapeutics, and Xencor; served on speakers’ bureaus for AbbVie, Amgen, Bausch Health/Valeant, Celgene, Galderma, Incyte, Janssen, Kyowa Hakko Kirin, Leo Pharma, Lilly, Merck, Novartis, Pfizer, and Sanofi Genzyme; received clinical research grants from AbbVie, Akros, Amgen, Anacor, Arcutis, Avillion, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite BioPharma, Celgene, Coherus, Dermavant, Dermira, Dice Therapeutics, Dow Pharma, Evelo, Galderma, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, Leo Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Aventis/Genzyme, Sun Pharma, Takeda, and UCB; received honoraria from AbbVie, Acelyrin, Akros, Amgen, Aralez Pharmaceuticals, Bausch Health/Valeant, Boehringer Ingelheim, Celgene, Celltrion, Coherus, Dermavant, Dice Therapeutics, Forbion, Galderma, Janssen, Kyowa Hakko Kirin, Leo Pharma, Lilly, Meiji Seika Pharma, Merck, Mitsubishi Pharma, Novartis, Pfizer, Reistone, Sanofi Genzyme, Sandoz, Sun Pharma, Takeda, UCB, vTv Therapeutics, and Xencor; served as a scientific officer for Akros, Anacor, Arcutis, Dice Therapeutics, and Kyowa Hakko Kirin; and served on steering committees for AbbVie, Amgen, Bausch Health/Valeant, Boehringer Ingelheim, Celgene, Janssen, Kyowa Hakko Kirin, Lilly, Merck, Novartis, Pfizer, Regeneron, Reistone, and Sanofi Genzyme; served on advisory boards for AbbVie, Amgen, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Dice Therapeutics, Dow Pharma, Galderma, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB.

: The POETYK PSO-1 and PSO-2 studies were conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines of the International Council for Harmonisation and in accordance with the European Union Directive 2001/20/EC and the US Code of Federal Regulations, Title 21, Part 50 (21CFR50), as well as applicable local requirements. The study protocols and amendments were approved by an institutional review board or independent ethics committee before initiation of the study at each site. All patients or their legal representatives provided written informed consent prior to study participation.